biophBiomedical PhotonicsBiomedical Photonics2413-9432Non-profit partnership for development of domestic photodynamic therapy and photodiagnosisbioph-70Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWSРоль брахитерапии в лечении локализованных форм рака предстательной железыRole of brachytherapy in the treatment of localized prostate cancerКапринА. Д.KaprinA. D.

МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» МЗ РФ, Москва, Россия

ГалкинВ. Н.GalkinV. N.ИвановС. А.IvanovS. A.mnioi@mail.ruНациональный медицинский исследовательский радиологический центр Минздрава России, Москва, РоссияРоссияP.A. Herzen MCRI (branch of FSBI «NMRRC» of the Ministry of Health of the Russian Federation), Moscow, RussiaRussian Federation201520122015442126Copyright © Каприн А.Д., Галкин В.Н., Иванов С.А., 20152015Каприн А.Д., Галкин В.Н., Иванов С.А.Kaprin A.D., Galkin V.N., Ivanov S.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pdt-journal.com/jour/article/view/70

Обзор посвящен применению метода брахитерапии в лечении локализованного рака предстательной железы (РПЖ). Приведены статистические данные по распространенности и выявляемости указанной патологии и их динамика за последние годы. Выполнен краткий анализ других методов, традиционно применяемых для лечения РПЖ: радикальной простатэктомии и дистанционной лучевой терапии. Обсуждены преимущества и недостатки этих методов. Приведена краткая историческая справка о развитии метода брахитерапии от первого опыта применения до широкого применения в клинической практике. Также в статье представлен подробный обзор ряда масштабных отечественных и зарубежных исследований, посвященных изучению эффективности и безопасности брахитерапии у пациентов с РПЖ за последние 15 лет. Описаны две формы проведения брахитерапии в современной клинической онкологии: низкодозная с имплантацией постоянных микроисточников и высокодозная с временной установкой изотопов, с особенностями их применения у разных групп пациентов. Подробно описана процедура брахитерапии и три ее основных этапа: планирование, имплантация и контрольная оценка после имплантации. Сделан вывод о перспективности применения брахитерапии в лечении РПЖ, как малоинвазивного и эффективного метода.

 

The review is devoted to application of brachytherapy for treating the localized prostate cancer (PC). Statistics for incidence and detectability of this pathology and its dynamics for recent years are represented. Brief analysis of other methods which are conveniently used for treatment of PC, such as radical prostatectomy and external-beam radiotherapy, was performed. Advantages and disadvantages of these methods have been discussed. Brief history about the development of brachytherapy from first experience to wide-spread use in clinical practice is reported. The detailed review of series of large trials from Russia and other countries for efficiency and safety of brachytherapy in patients with prostate cancer for recent 15 years is also represented. Two types of brachytherapy in current clinical oncology i.e. low-dose technique with permanent implantation of microsources and high-dose temporary isotope implantation, specifics of its application in different groups of patients have been described. The procedure of brachytherapy and its three main steps i.e. planning, implantation and control assessment after implantation have been characterized in details. The conclusion about benefits of using of brachytherapy in the treatment of prostate cancer as minimally invasive and efficient method was made.

 

брахитерапиямикроисточникирак предстательной железырадикальная простатэктомияbrachytherapymicrosourcesprostate cancerradical prostatectomyReferencesЗаболеваемость населения России в 2003 году. Статистические материалы. – М.: ГЭОТАР-МЕД, 2004. – 68 с.Zabolevaemost' naseleniya Rossii v 2003 godu. Statisticheskie materialy (Incidence in Russian population in 2003. Statistical data), M.: GEOTAR-MED, 2004, p. 1–68.Злокачественные новообразования в России в 2013 году (заболеваемость и смертность) / Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. – М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «ФМИЦ им. П.А. Герцена» Минздрава России, 2015. – 250 с.Zlokachestvennye novoobrazovaniya v Rossii v 2013 godu (zabolevaemost' i smertnost') (Malignant neoplasms in Russia in 2013 (incidence and mortality), Pod red. A.D. Kaprina, V.V. Starinskogo, G.V. Petrovoi, M.: MNIOI im. P.A. Gertsena – filial FGBU «FMITs im. P.A. Gertsena» Minzdrava Rossii, 2015, p. 1–250.DeAngelis R., Sant M., Coleman M.P. et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study // Lancet Oncol. – 2014. – Vol. 15 (1). – P. 23-34.DeAngelis R., Sant M., Coleman M.P. et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE- 5-a population-based study, Lancet Oncol, 2014, Vol. 15 (1), p. 23–34.Godtman R.A., Holmberg E., Khatami A. et al. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial // Eur Urol. – 2013. – Vol. 63 (1). – P. 101–107.Godtman R.A., Holmberg E., Khatami A. et al. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial, Eur Urol, 2013, Vol. 63 (1), p. 101–107.Klotz L. Active surveillance for prostate cancer: trials and tribulations // World J Urol. – 2008. – Vol. 26 (5). – P. 437–442. 6. Nag S. A brief history of brachytherapy // Brachytherapy. – 2009. – Vol. 7 (1). – P. 55–59.Klotz L. Active surveillance for prostate cancer: trials and tribulations, World J Urol, 2008, Vol. 26 (5), p. 437–442.Gupta V.K. Brachytherapy – past, present and future // Journal of Medical Physics. – 1995. – Vol. 20. – P. 31–38.Nag S. A brief history of brachytherapy, Brachytherapy, 2009, Vol. 7 (1), p. 55–59.Zelefsky M.J., Nedelka M.A., Arican Z.L. et al. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensitymodulated radiation therapy // Brachytherapy. – 2008. – Vol. 7 (1). – P. 1–6.Gupta V.K. Brachytherapy – past, present and future, Journal of Medical Physics, 1995, Vol. 20, p. 31–38.Sh D., Flynn A., Batterman J. et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer // Radiother Oncol. – 2000. – Vol. 57 (3). – P. 315–321.Zelefsky M.J., Nedelka M.A., Arican Z.L. et al. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy, Brachytherapy, 2008, Vol. 7 (1), p. 1–6.Grimm P.D., Blasko J.C., Sylvester J.E. et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with 125-I brachytherapy // Int J Radiat Biol Phys. - 2001. – Vol. 51 (1). – P. 31–40.Sh D., Flynn A., Batterman J. et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer, Radiother Oncol, 2000, Vol. 57 (3), p. 315–321.Potters L., Klein E.A., Kattan M.W. et al. Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation // Radiother Oncol. – 2004. – Vol. 71 (1). – P. 29–33.Grimm P.D., Blasko J.C., Sylvester J.E. et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with 125-I brachytherapy, Int J Radiat Biol Phys, 2001, Vol. 51 (1), p. 31–40.Sylvester J.E., Blasko J.C., Grimm R. et al. Fifteen year follow-up of the first cohort of localized prostate cancer patients treated with brachytherapy // J Clin Oncol. – 2004. – Vol. 22 (14). – P. 45–67.Potters L., Klein E.A., Kattan M.W. et al. Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation, Radiother Oncol, 2004, Vol. 71 (1), p. 29–33.Potters L., Morgenstern C., Calugaru E. et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer // J Urol. – 2005. – Vol. 173 (5). – P. 1562–1566.Sylvester J.E., Blasko J.C., Grimm R. et al. Fifteen year follow-up of the first cohort of localized prostate cancer patients treated with brachytherapy, J Clin Oncol, 2004, Vol. 22 (14), p. 45–67.Stone N.N., Stock R.G., Unger P. Intermediate term biochemicalfree progression and local control following 125-iodine brachytherapy for prostate cancer // J Urol. – 2005. – Vol. 173 (3). – P. 803–807.Potters L., Morgenstern C., Calugaru E. et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer, J Urol, 2005, Vol. 173 (5), p. 1562–1566.Zelefsky M.J., Kuban D.A., Levy L.B. et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation // Int J Radiat Oncol Biol Phys. – 2007. – Vol. 67 (2). – P. 327–333.Stone N.N., Stock R.G., Unger P. Intermediate term biochemical-free progression and local control following 125-iodine brachytherapy for prostate cancer, J Urol, 2005, Vol. 173 (3), p. 803–807.Lawton C.A., DeSilvio M., Lee W.R. et al. Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05) // Int J Radiat Oncol Biol Phys. – 2007. – Vol. 67 (1). – P. 39–47.Zelefsky M.J., Kuban D.A., Levy L.B. et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation, Int J Radiat Oncol Biol Phys, 2007, Vol. 67 (2), p. 327–333.Peinemann F., Grouven U., Hemkens L.G. Low-dose rate brachytherapy for men with localized prostate cancer. – Cochrane Database Syst Rev, 2011.Lawton C.A., DeSilvio M., Lee W.R. et al. Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05), Int J Radiat Oncol Biol Phys, 2007, Vol. 67 (1), p. 39–47.Grimm P., Sylvester J. Advances in Brachytherapy // Rev Urol. – 2004. – Vol. 6, Suppl 4. – P. 37–48.Peinemann F., Grouven U., Hemkens L.G. Low-dose rate brachytherapy for men with localized prostate cancer, Cochrane Database Syst Rev, 2011.Ferrer M., Suárez J.F., Guedea F. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer // Int J Radiat Oncol Biol Phys. – 2008. – Vol. 72 (2). – P. 421–432.Grimm P., Sylvester J. Advances in Brachytherapy, Rev Urol, 2004, Vol. 6, Suppl. 4, p. 37–48.Takam R., Bezak E., Yeoh E. Risk of second primary cancer following prostate cancer radiotherapy: DVH analysis using the competitive risk model // Phys Med Biol. – 2009. – Vol. 54 (3). – P. 611–625.Ferrer M., Suárez J.F., Guedea F. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer, Int J Radiat Oncol Biol Phys, 2008, Vol. 72 (2), p. 421–432.Baxter N.N., Trepper J.E., Durham S.B. et al. Increased risk of rectal cancer after prostate radiation: a population-based study // Gastroenterology. – 2005. – Vol. 128 (4). – P. 819–824.Takam R., Bezak E., Yeoh E. Risk of second primary cancer following prostate cancer radiotherapy: DVH analysis using the competitive risk model, Phys Med Biol, 2009, Vol. 54 (3), p. 611–625.Liauw S.L., Sylvester J.E., Morris C.G. et al. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up // Int J Radiat Oncol Biol Phys. – 2006. – Vol. 66 (3). – P. 669–673.Baxter N.N., Trepper J.E., Durham S.B. et al. Increased risk of rectal cancer after prostate radiation: a population-based study, Gastroenterology, 2005, Vol. 128 (4), p. 819–824.Hinnen K.A., Schaapveld M., van Vulpen M. Prostate brachytherapy and second primary cancer risk: a competitive risk analysis // J Clin Oncol. – 2011. – Vol. 29 (34). – P. 4510–4515.Liauw S.L., Sylvester J.E., Morris C.G. et al. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up, Int J Radiat Oncol Biol Phys, 2006, Vol. 66 (3), p. 669–673.Аполихин О.И., Сивков А.В., Ощепков В.Н. и др. 10-летний опыт брахитерапии рака предстательной железы: клинические результаты и экономические оценки // Вестник РНЦРР Минздрава России. – 2011. – Т. 3, № 11. – С. 114–127.Hinnen K.A., Schaapveld M., van Vulpen M. Prostate brachytherapy and second primary cancer risk: a competitive risk analysis, J Clin Oncol, 2011, Vol. 29 (34), p. 4510–4515.Разрешение на применение новой медицинской технологии ФС № 2009/218 от 27.07.2009. Брахитерапия локализованного рака предстательной железы / А.Д. Каприн, Г.А. Паньшин, И.А. Альбицкий и соавт. – 21 с.Apolikhin O.I., Sivkov A.V., Oshchepkov V.N. i dr. 10-letnii opyt brakhiterapii raka predstatel'noi zhelezy: klinicheskie rezul'taty i ekonomicheskie otsenki (10-year experience on brachytherapy for prostate cancer: clinical results and economic assessments), Vestnik RNTsRR Minzdrava Rossii, 2011, T. 3, No. 11, p. 114–127.Razreshenie na primenenie novoi meditsinskoi tekhnologii FS № 2009/218 ot 27.07.2009. Brakhiterapiya lokalizovannogo raka predstatel'noi zhelezy (Permission for use of new medical technology FS № 2009/218 dated 27.07.2009. Brachytherapy of localized prostate cancer), A.D. Kaprin, G.A. Pan'shin, I.A. Al'bitskii i soavt., p. 1–21.Razreshenie na primenenie novoi meditsinskoi tekhnologii FS № 2009/218 ot 27.07.2009. Brakhiterapiya lokalizovannogo raka predstatel'noi zhelezy (Permission for use of new medical technology FS № 2009/218 dated 27.07.2009. Brachytherapy of localized prostate cancer), A.D. Kaprin, G.A. Pan'shin, I.A. Al'bitskii i soavt., p. 1–21.

The authors declare that there are no conflicts of interest present.